title: Changes in intrinsic subtype of breast cancer during tumor progression in the same patient.
abstract: Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) and Ki67 are important prognostic factors and key variables in classification of the intrinsic subtype, which is essential for choice of adjuvant therapy in breast cancer management. There has been earlier reports that instability of hormonal and HER2 status during progression of tumor. However, breast cancer treatment guidelines recently recommended using the intrinsic subtype that is determined by four immunohistochemical (IHC) assays, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. The purpose of study was to investigate whether the intrinsic subtype changes during the tumor progression from ductal carcinoma in situ (DCIS) to lymph node metastasis. The study included 90 patients with breast cancer in Korea University Guro Hospital, between 1992 and 2008. All individuals had DCIS, invasive carcinoma and lymph node metastasis lesion. IHC staining for ER, PR, HER2 and Ki67 as well as SISH assay for HER2 gene amplification was done with following standard method. Overall 25% of breast cancer changed their intrinsic phenotype during progression. Study demonstrated that a subset of breast cancers can change their intrinsic subtype during cancer progression. These changes have an impact on patient prognosis and management, because each breast cancer subtype has their own differently optimized treatment options according to St. Gallen and NCCN guideline.
authors.affiliation: Department of Pathology, College of Medicine, Korea University Korea.
authors.forename: Chungyeul
authors.initials: C
authors.lastname: Kim
authors.affiliation: Department of Pathology, College of Medicine, Korea University Korea.
authors.forename: Jungjoo
authors.initials: J
authors.lastname: Lee
authors.affiliation: College of Medicine, Korea University Seoul, Korea.
authors.forename: Wonyoung
authors.initials: W
authors.lastname: Lee
authors.affiliation: Department of Pathology, College of Medicine, Korea University Korea.
authors.forename: Aeree
authors.initials: A
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008207:Lymphatic Metastasis / Q000473:pathology; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Breast cancer; intrinsic subtype; tumor progression
references.citation: Breast Dis. 2012;34(1):9-17
references.pmid: 23507670
references.citation: Nature. 1980 Jan 10;283(5743):139-46
references.pmid: 6985715
references.citation: J Clin Oncol. 1989 Aug;7(8):1120-8
references.pmid: 2569032
references.citation: Crit Rev Oncol Hematol. 1999 Aug;31(3):209-23
references.pmid: 10532196
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references.pmid: 19204204
references.citation: Cell. 2009 Nov 25;139(5):871-90
references.pmid: 19945376
references.citation: Nat Rev Cancer. 2002 Aug;2(8):563-72
references.pmid: 12154349
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: Cancer. 1985 Oct 15;56(8):2019-24
references.pmid: 2992754
references.citation: Breast Cancer Res Treat. 2012 Aug;135(1):301-6
references.pmid: 22752290
references.citation: Chemotherapy. 2012;58(5):364-70
references.pmid: 23207824
references.citation: Hum Pathol. 2003 Nov;34(11):1163-9
references.pmid: 14652818
references.citation: Ann Oncol. 2011 Aug;22(8):1736-47
references.pmid: 21709140
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2601-8
references.pmid: 22711854
references.citation: Steroids. 2001 Dec;66(12):905-10
references.pmid: 11711119
references.citation: Eur J Cancer. 1979 Mar;15(3):299-310
references.pmid: 446512
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5222-32
references.pmid: 20837693
references.citation: Int J Oncol. 1996 May;8(5):997-1002
references.pmid: 21544457
references.citation: J Natl Cancer Inst. 2008 Jan 2;100(1):14-20
references.pmid: 18159072
references.citation: J Clin Oncol. 2012 Feb 20;30(6):587-92
references.pmid: 22124102
references.citation: Cancer Res. 2010 Jul 15;70(14):5649-69
references.pmid: 20610625
references.citation: Maturitas. 2012 Dec;73(4):288-94
references.pmid: 23020990
references.citation: World J Surg Oncol. 2011;9:131
references.pmid: 22004841
references.citation: Cancer Res. 1996 Apr 1;56(7):1493-7
references.pmid: 8603391
references.citation: Virchows Arch. 2011 Jul;459(1):1-10
references.pmid: 21643691
references.citation: Breast Cancer Res Treat. 2012 Sep;135(2):619-27
references.pmid: 22890751
references.citation: Am J Epidemiol. 2013 Jul 15;178(2):296-308
references.pmid: 23645624
references.citation: Int J Cancer. 2013 Sep 15;133(6):1470-8
references.pmid: 23483540
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references.pmid: 20404251
references.citation: Nat Rev Cancer. 2002 Jun;2(6):442-54
references.pmid: 12189386